Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an announcement.
Qyuns Therapeutics Co., Ltd. has issued a supplemental announcement to its annual report for the year ended December 31, 2024. The announcement provides detailed information about the emoluments paid to its directors and chief executive, highlighting the compensation structure including salaries, bonuses, and share-based payments. This disclosure aims to maintain transparency with stakeholders and ensure compliance with regulatory requirements.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on developing therapeutic solutions and is publicly traded on the Hong Kong Stock Exchange.
Average Trading Volume: 198,433
Technical Sentiment Signal: Buy
For an in-depth examination of 2509 stock, go to TipRanks’ Overview page.